Search results for "fusions"

showing 10 items of 176 documents

Intravenous high-dose furosemide and hypertonic saline solutions for refractory heart failure and ascites.

2011

Several studies have shown the efficacy of hypertonic saline solution infusion in conditions in which regional organ blood flow is impaired. Our group has shown that treatment of patients with diuretic-resistant heart failure with high-dose furosemide plus hypertonic saline is effective and well tolerated, improving symptoms of congestion, reducing plasma levels of markers of neurohormonal and inflammatory activation, decreasing hospital readmission rates, and reducing long-term mortality. The same regimen was shown to be better than repeated paracentesis in patients with cirrhosis and refractory ascites, yielding better control of ascites, pleural effusions, and/or leg edema without an inc…

Liver CirrhosisCirrhosisFurosemideAscitesmedicineParacentesisHumansAdverse effectDiureticsInfusions IntravenousHepatic encephalopathyHeart FailureSaline Solution Hypertonicmedicine.diagnostic_testCardio-Renal Syndromebusiness.industryFurosemideAscitesmedicine.diseaseHypertonic salineNephrologyAnesthesiaHeart failuremedicine.symptombusinessmedicine.drugSeminars in nephrology
researchProduct

Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-Deficient Diets

2014

Background & Aims Nonalcoholic fatty liver disease is a common consequence of human and rodent obesity. Disruptions in lipid metabolism lead to accumulation of triglycerides and fatty acids, which can promote inflammation and fibrosis and lead to nonalcoholic steatohepatitis. Circulating levels of fibroblast growth factor (FGF)21 increase in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis; therefore, we assessed the role of FGF21 in the progression of murine fatty liver disease, independent of obesity, caused by methionine and choline deficiency. Methods C57BL/6 wild-type and FGF21-knockout (FGF21-KO) mice were placed on methionine- and choline-deficient (MCD)…

Liver Cirrhosismedicine.medical_specialtyTime FactorsBiologyInfusions SubcutaneousSeverity of Illness IndexArticleHepatitischemistry.chemical_compoundAcyl-CoAMethionineNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseasemedicineAnimalsRNA MessengerMice Knockoutchemistry.chemical_classificationHepatologyFatty acid metabolismFatty AcidsFatty liverGastroenterologyFatty acidmedicine.diseaseRecombinant ProteinsCholine DeficiencyFibroblast Growth FactorsMice Inbred C57BLDisease Models AnimalEndocrinologyLiverchemistryLipotoxicityDisease ProgressionLipid PeroxidationInflammation MediatorsSteatosisLong chain fatty acidOxidation-ReductionGastroenterology
researchProduct

Efficacy of N-acetylcysteine in the prevention of alcohol relapse-like drinking: Study in long-term ethanol-experienced male rats

2021

Alcohol use disorders are chronic and highly relapsing disorders, thus alcoholic patients have a high rate of recidivism for drug use even after long periods of abstinence. The literature points to the potential usefulness of N-acetylcysteine (NAC) in the management of several substance use disorders probably due to its capacity to restore brain homeostasis of the glutamate system disrupted in addiction. However, there is little evidence in the case of alcohol. The aim of this study was to explore the potential anti-relapse efficacy of NAC using the alcohol deprivation effect (ADE) model in long-term experienced rats. Two experiments were performed in male Wistar rats to: (a) test the effic…

Male0301 basic medicineDrugAlcohol DrinkingInjections Subcutaneousmedia_common.quotation_subjectDrug Evaluation PreclinicalAlcoholPharmacologyInfusions Subcutaneous:CIENCIAS DE LA VIDA [UNESCO]ethanol relapse preventionAcetylcysteineRandom Allocation03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compoundSubcutaneous injection0302 clinical medicinePharmacotherapyalcohol use disordersRecurrenceglutamate neurotransmissionUNESCO::CIENCIAS DE LA VIDAAnimalsMedicineRats Wistarmedia_commonEthanolEthanolbusiness.industryAbstinencealcohol deprivation effecAcetylcysteineRatsSubstance Withdrawal SyndromeAlcoholismRegimen030104 developmental biologychemistryModels Animalbusiness030217 neurology & neurosurgerymedicine.drug
researchProduct

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma : Final …

2016

Purpose Blinatumomab is a CD19/CD3 BiTE (bispecific T-cell engager) antibody construct for the treatment of Philadelphia chromosome–negative acute B-lymphoblastic leukemia. We evaluated blinatumomab in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Patients and Methods This 3 + 3 design, phase I dose-escalation study determined adverse events and the maximum tolerated dose (MTD) of continuous intravenous infusion blinatumomab in patients with relapsed/refractory NHL. Blinatumomab was administered over 4 or 8 weeks at seven different dose levels (0.5 to 90 μg/m2/day). End points were incidence of adverse events, pharmacokinetics, pharmacodynamics, and overall response rate. Results B…

Male0301 basic medicineOncologyCancer ResearchCD3 ComplexT-Lymphocytesmedicine.medical_treatmentMedizinLymphoma Mantle-CellLymphocyte Activation0302 clinical medicineRecurrenceGermanyhemic and lymphatic diseasesAntibodies BispecificMedicineMolecular Targeted TherapyInfusions IntravenousLymphoma FollicularLymphoma Non-HodgkinRemission InductionMiddle AgedLeukemiaTreatment OutcomeOncology030220 oncology & carcinogenesisFemaleBlinatumomabImmunotherapymedicine.drugAdultmedicine.medical_specialtyLymphoma B-CellMaximum Tolerated DoseAntigens CD19Antineoplastic AgentsDrug Administration Schedule03 medical and health sciencesPharmacokineticsRefractoryInternal medicineHumansAdverse effectbusiness.industryImmunotherapymedicine.diseaseLymphomaSurgery030104 developmental biologyPharmacodynamicsNervous System Diseasesbusiness
researchProduct

Cerebrospinal fluid pharmacokinetics of ceftaroline in neurosurgical patients with an external ventricular drain

2019

IF 5.217; International audience; BackgroundOwing to its antibacterial properties, ceftaroline could be attractive for prevention or treatment of bacterial post-neurosurgical meningitis/ventriculitis. However, few data are available concerning its meningeal concentrations.ObjectivesTo investigate ceftaroline CSF pharmacokinetics in ICU patients with an external ventricular drain (EVD).MethodsPatients received a single 600 mg dose of ceftaroline as a 1 h intravenous infusion. Blood and CSF samples were collected before and 0.5, 1, 3, 6, 12 and 24 h after the end of the infusion. Concentrations were assayed in plasma and CSF by LC–MS/MS. A two-step compartmental pharmacokinetic analysis was c…

Male0301 basic medicinemedicine.medical_treatmentprotein bindinginfusion proceduresintensive care unitCerebral VentriclesCerebral VentriculitisPostoperative Complications0302 clinical medicineCerebrospinal fluidTandem Mass SpectrometryPharmacology (medical)030212 general & internal medicineInfusions Intravenousintravenous infusion proceduresmeningitisMiddle AgedAnti-Bacterial Agents3. Good healthIntensive Care UnitsInfectious DiseasesAnesthesiaDrainageceftarolineFemalepharmacokineticsMeningitisAdultMicrobiology (medical)VentriculostomyAdolescent030106 microbiologyCmax[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgerycerebrospinal fluidMeningitis BacterialYoung Adult03 medical and health sciencesPharmacokineticsavian ventriculitismedicineVentriculitisHumansDistribution (pharmacology)plasmaAgedbacterial post-neurosurgical meningitis/ventriculitisPharmacologybusiness.industryModels Theoreticalmedicine.diseaseneurosurgical proceduresCephalosporinsventriculostomybusinessChromatography LiquidExternal ventricular drainJournal of Antimicrobial Chemotherapy
researchProduct

Evaluation of low dose anaphylatoxic peptides in the pathogenesis of the adult respiratory distress syndrome (ARDS). Monitoring of early C5a effects …

1986

A guinea-pig in vivo model is presented that allows the infusion of purified C5a via a central vein catheter and the monitoring of its effects on granulocytes and platelets, the most important cells in the pathogenesis of several lung disorders, e.g. shock lung. After the infusion of C5a, which was adjusted to a quantity that caused slight and transient alterations of lung physiology, granulocytes disappeared from circulation within 1 min. Simultaneously the granulocyte content of the lung increased about three-fold as judged by histological evaluations. Morphologic destructions were not observed. After the drop a rebound of circulating Polymorpho-nuclear leucocytes (PMN) occurred, which wa…

MaleARDSPathologymedicine.medical_specialtyGuinea PigsClinical BiochemistryComplement C5aGranulocyteBiochemistryPathogenesisLung DisorderLeukocyte CountIn vivomedicineAnimalsInfusions IntravenousLungRespiratory Distress SyndromeLungRespiratory distressPlatelet Countbusiness.industryComplement C5General Medicinerespiratory systemmedicine.diseaseDisease Models Animalmedicine.anatomical_structureFemaleBone marrowbusinessGranulocytesEuropean Journal of Clinical Investigation
researchProduct

Efficacy of Periportal Infiltration and Intraperitoneal Instillation of Ropivacaine After Laparoscopic Surgery in Children

2009

Postoperative pain is less intense after laparoscopic than after open surgery. However, minimally invasive surgery is not a a pain-free procedure. Many trials have been done in adults using intraperitoneal and/or incisional local anesthetic, but similar studies have not yet been reported in the literature in children. Aim: The aim of this study was to evaluate the analgesic effect of periportal infiltration and intraperitoneal instillation of ropivacaine in children undergoing laparoscopic surgery. Materials and Methods: Thirty patients who underwent laparoscopic surgery were randomly allocated to one of three groups. Group A (n 10) received local infiltration of port sites with 10 mL of ro…

MaleAnalgesic effectLaparoscopic surgerymedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentAnalgesicBody Mass Indexlaw.inventionRandomized controlled triallawmedicineHumansInfusions ParenteralRopivacaineAnesthetics LocalChildPain MeasurementPain Postoperativebusiness.industryLocal anestheticRopivacaineOpen surgerySettore MED/20 - Chirurgia Pediatrica E Infantilelaparoscopic surgery periportal infiltrationmedicine.diseaseAmidesSurgeryInstillation DrugTreatment OutcomeAnesthesiaFemaleLaparoscopySurgerybusinessInfiltration (medical)medicine.drugJournal of Laparoendoscopic & Advanced Surgical Techniques
researchProduct

Nifedipine improves blood flow and oxygen supply, but not steady-state oxygenation of tumours in perfusion pressure-controlled isolated limb perfusio…

2002

Isolated limb perfusion allows the direct application of therapeutic agents to a tumour-bearing extremity. The present study investigated whether the dihydropyridine-type Ca2+-channel blocker nifedipine could improve blood flow and oxygenation status of experimental tumours during isolated limb perfusion. Perfusion was performed by cannulation of the femoral artery and vein in rats bearing DS-sarcoma on the hind foot dorsum. Perfusion rate was adjusted to maintain a perfusion pressure of 100–140 mmHg throughout the experiment. Following equilibration, nifedipine was continuously infused for 30 min (8.3 μg min−1 kg−1 BW). During constant-pressure isolated limb perfusion, nifedipine can signi…

MaleCancer ResearchNifedipinecalcium channel blockerCell RespirationHemodynamicsFemoral arteryMicrocirculationRats Sprague-DawleyNifedipinemedicine.arterymedicineLaser-Doppler FlowmetryAnimalsExperimental TherapeuticsInfusions Intravenoustumour vascular resistancebusiness.industrytumour perfusionBlood flowOxygenationHypoxia (medical)Calcium Channel BlockersRatsOxygenOncologyRegional Blood FlowAnesthesiaChemotherapy Cancer Regional PerfusionSarcoma Experimentalmedicine.symptombusinessPerfusiontumour oxygenationmedicine.drugisolated limb perfusionBritish journal of cancer
researchProduct

Treatment of Malignant Ascites with a Second Cycle of Catumaxomab in Gastric Signet Cell Carcinoma - a Report of 2 Cases

2014

<b><i>Summary</i></b><b><i>Background: </i></b>Malignant ascites is a frequent complication in gastrointestinal malignancy and is unresponsive to systemic therapies. Therapeutic options are limited, and repeated paracentesis is associated with increased loss of fluids and proteins, and impaired quality of life. The bi-specific trifunctional antibody catumaxomab has been approved for the treatment of refractory ascites. It has been proposed that repeated application leads to formation of human anti-mouse antibodies with a decrease in effectiveness and potentially hypersensitivity reactions. <b><i>Case Report: </i></b>Her…

MaleCancer Researchmedicine.medical_specialtyCatumaxomabGastroenterologyStomach NeoplasmsInternal medicineAntibodies BispecificAscitesmedicineParacentesisCarcinomaHumansInfusions ParenteralPeritoneal Neoplasmsmedicine.diagnostic_testSignet ring cellbusiness.industryAscitesCancerHematologyMiddle Agedmedicine.diseaseTrifunctional antibodySurgeryOncologyRetreatmentFemalemedicine.symptomComplicationbusinessCarcinoma Signet Ring Cellmedicine.drugOncology Research and Treatment
researchProduct

Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-…

2004

Abstract Based on the results of combined data from three North American Phase II studies, a randomised Phase II study in the same patient population was performed, using combination chemotherapy with estramustine phosphate (EMP) and vinblastine (VBL) in hormone refractory prostate cancer patients. In all, 92 patients were randomised into a Phase II study of oral EMP (10 mg kg day continuously) or oral EMP in combination with intravenous VBL (4 mg m(2) week for 6 weeks, followed by 2 weeks rest). The end points were toxicity and PSA response in both groups, with the option to continue the trial as a Phase III study with time to progression and survival as end points, if sufficient responses…

MaleCancer Researchmedicine.medical_specialtyUrologyAdministration OralPhases of clinical researchVinblastineMetastasisClinicalProstate cancerAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions IntravenousSurvival analysishormone-escaped prostate cancerEMP/VBL vs EMPbusiness.industryProstatic NeoplasmsCombination chemotherapyProstate-Specific Antigenmedicine.diseaseSurvival AnalysisPhase IISurgeryVinblastineProstate-specific antigenOncologyDrug Resistance NeoplasmDisease ProgressionEstramustineEstramustinebusinessmedicine.drug
researchProduct